If we skip down the track a bit to actual income, or just get ahead of ourselves, project, whatever, I think that is a rather significant underestimate if we go by what Silviu thinks the recurring income from COVID-19/ARDS is. Not including ARDS from Influenza or other causes. This is part of his answer to the last question by Allen;
"We're going to make it available, and make it available as economically and as appropriately as possible, but obviously it's a billion dollar market opportunity for us on an ongoing basis."
Ann: Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment, page-76
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |